Thank You for Attending!
Day 1: Charting the Path for ctDNA as an Early Endpoint
Tuesday, November 9, 2021
Click Here to Watch in Full
Click HERE for the event recap and HERE for the white paper
Day 2: Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization
Wednesday, November 10, 2021
Click Here to Watch in Full
Click HERE for the event recap and HERE for the white paper
Final Agenda – Day 1: Charting the Path for ctDNA as an Early Endpoint
Tuesday, November 9, 2021
12:00PM – Welcoming Remarks
- Jeff Allen, Friends of Cancer Research
12:05 PM – Keynote Conversation
- Janet Woodcock, Acting Commissioner, U.S. FDA
- Ellen Sigal, Friends of Cancer Research
12:25 PM – Session 1: Charting the Path for ctDNA as an Early Endpoint
Overview: The Value of ctDNA Monitoring in Cancer
- Matthew Hellmann, Memorial Sloan Kettering Cancer Center
12:35PM – Panel Discussion
- Kathleen Winson, Genentech, A Member of the Roche Group (moderator)
- Chris Abbosh, AstraZeneca
- Valsamo Anagnostou, Johns Hopkins School of Medicine
- Jonathan Baden, Bristol Myers Squibb
- Reena Philip, CDRH, U.S. FDA
- Mark Sausen, Personal Genome Diagnostics
- Paz Vellanki, CDER, U.S. FDA
1:05PM – Closing Remarks
- Jeff Allen, Friends of Cancer Research
Final Agenda – Day 2: Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization
Wednesday, November 10, 2021
12:00PM – Welcoming Remarks
- Jeff Allen, Friends of Cancer Research
12:05 PM – Session 2: Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization
Overview: Optimizing Dosing of Oncology Drugs
- Atik Rahman, U.S. FDA
12:15PM – Panel Discussion
- Mark Ratain, University of Chicago (moderator)
- Lokesh Jain, Merck
- Anne Loeser, Patient Advocate
- Mirat Shah, CDER, U.S. FDA
- Laurie Strawn, Pfizer
12:45PM – Fireside Chat with the Oncology Center of Excellence
- Richard Pazdur, Director, Oncology Center of Excellence, U.S. FDA
- Julia Beaver, Chief of Medical Oncology, Oncology Center of Excellence, U.S. FDA
- Tamy Kim, Director for Regulatory Affairs and Regulatory Policy, Oncology Center of Excellence, U.S. FDA
- Paul G. Kluetz, Deputy Center Director, Oncology Center of Excellence, U.S. FDA
- Marc Theoret, Deputy Center Director, Oncology Center of Excellence, U.S. FDA
1:10PM – Closing Remarks
- Jeff Allen, Friends of Cancer Research
